Nebivolol
A beta-1 adrenergic receptor antagonist.
General information
Nebivolol is a beta-1 adrenergic receptor antagonist. It is used as a blood pressure-lowering drug (NCIt).
Nebivolol on DrugBank
Nebivolol on PubChem
Nebivolol on Wikipedia
Marketed as
BYSTOLIC; LOBIVON; NEBICARD; NEBILET; NEBILONG; NODON; NUBETA
C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2
Preprint |
human renal cortical epithelial cells | Apr/23/2020 | ||
|
Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach
RdRpol nsp8 Small molecule In silico |
in silico | 3.22 | Predicted to inhibit the SARS-CoV-2 RNA-dependent RNA polymerase and nsp8 protein-protein interaction. |
Sep/16/2020 |
|
A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing
3CLpro Nucleocapsid protein nsp16 nsp10 Small molecule In silico |
in silico | 2.74 | Predicted to bind SARS-CoV-2 3C-like protease and Nucleocapsid protein. |
Mar/18/2021 |
AI-suggested references
Clinical trials
| ID | Title | Status | Phase | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04631536 | Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC | Active, not recruiting | Phase 3 | Jan/10/2021 | Jul/01/2022 |
|
|||||
